

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number
WO 03/072733 A2

- (51) International Patent Classification⁷: **C12N**
- (21) International Application Number: PCT/US03/05508
- (22) International Filing Date: 21 February 2003 (21.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/358,651 21 February 2002 (21.02.2002) US
- (71) Applicant (*for all designated States except US*): **PHARMACIA & UPJOHN COMPANY** [US/US]; 301 Henrietta Street, Kalamazoo, MI 49007 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **CHOU, Kuo-Chen** [US/US]; 7088 Arbor Valley Avenue, Kalamazoo, MI 49009 (US). **HOWE, Jeffrey, W.** [CA/US]; 1021 Edgemoor Ave, Kalamazoo, MI 49008 (US).
- (74) Agent: **SARUSSI, Steven, J.**; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Suite 3200, Chicago, IL 60606 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 03/072733 A2

BEST AVAILABLE COPY

(54) Title: MODIFIED BACE

(57) Abstract: The present invention relates to recombinant human BACE polypeptides. More particularly, the invention relates to recombinant human BACE polypeptides that have a modified amino acid sequence at position 33 of the BACE sequence, as well as to polynucleotides, expression vectors, host cells, and methods for producing the modified recombinant human BACE polypeptides.

BIS

MODIFIED BACE

[001] This application claims priority to U.S. Provisional Patent Application serial number 60/358,651, filed February 21, 2002.

FIELD OF THE INVENTION

[002] The invention is related to a recombinant human BACE. More particularly, the invention is related to an active human BACE having a modification at amino acid position 33.

BACKGROUND OF THE INVENTION

[003] Alzheimer's disease (AD) is a progressive degenerative disease of the brain primarily associated with aging. Clinical presentation of AD is characterized by loss of memory, cognition, reasoning, judgment, and orientation. As the disease progresses, motor, sensory, and linguistic abilities are also affected until there is global impairment of multiple cognitive functions. These cognitive losses occur gradually, but typically lead to severe impairment and eventual death in the range of four to twelve years.

[004] Alzheimer's disease is characterized by two major pathologic observations in the brain: neurofibrillary tangles and beta amyloid (or neuritic) plaques, comprised predominantly of an aggregate of a peptide fragment known as A beta. Individuals with AD exhibit characteristic beta-amyloid deposits in the brain (beta amyloid plaques) and in cerebral blood vessels (beta amyloid angiopathy) as well as neurofibrillary tangles. Neurofibrillary tangles occur not only in Alzheimer's disease but also in other dementia-inducing disorders. On autopsy, large numbers of these lesions are generally found in areas of the human brain important for memory and cognition.

[005] Smaller numbers of these lesions in a more restricted anatomical distribution are found in the brains of most aged humans who do not have clinical AD. Amyloidogenic plaques and vascular amyloid angiopathy also characterize the brains of individuals with Trisomy 21 (Down's Syndrome), Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D), and other neurogenerative disorders. Beta-amyloid is a defining feature of AD, now believed to be a causative precursor or factor in the development of the disease. Deposition of A beta in areas of the brain responsible for cognitive activities is a major factor in the development of AD. Beta-amyloid plaques are predominantly composed of amyloid beta peptide (A beta, also sometimes designated betaA4). A beta peptide is derived by proteolysis of the amyloid precursor protein (APP) and is comprised of 39-42 amino acids. Several proteases called secretases are involved in the processing of APP.

[006] Cleavage of APP at the N-terminus of the A beta peptide by beta-secretase and at the C-terminus by one or more gamma-secretases constitutes the beta-amyloidogenic pathway, i.e. the pathway by which A beta is formed. Cleavage of APP by alpha-secretase produces alpha-sAPP, a secreted form of APP that does not result in beta-amyloid plaque formation. This alternate pathway precludes the formation of A beta peptide. A description of the proteolytic processing fragments of APP is found, for example, in U.S. Patent Nos. 5,441,870; 5,721,130; and 5,942,400.

[007] An aspartyl protease has been identified as the enzyme responsible for processing of APP at the beta-secretase cleavage site. The beta-secretase enzyme has been disclosed using varied nomenclature, including BACE, Asp, and Memapsin. See, for example, Sinha et.al., 1999, *Nature* 402:537-554 (p501) and published PCT application WO00/17369.

[008] Several lines of evidence indicate that progressive cerebral deposition of beta-amyloid peptide (A beta) plays a seminal role in the pathogenesis of AD and can precede

cognitive symptoms by years or decades. See, for example, Selkoe, 1991, *Neuron* 6:487.

Release of A beta from neuronal cells grown in culture and the presence of A beta in cerebrospinal fluid (CSF) of both normal individuals and AD patients has been demonstrated. See, for example, Seubert et al., 1992, *Nature* 359:325-327.

[009] It has been proposed that A beta peptide accumulates as a result of APP processing by beta-secretase, thus inhibition of this enzyme's activity is desirable for the treatment of AD. *In vivo* processing of APP at the beta-secretase cleavage site is thought to be a rate-limiting step in A beta production, and is thus a therapeutic target for the treatment of AD. See for example, Sabbagh, M., et al., 1997, *Alz. Dis. Rev.* 3, 1-19.

[0010] Published international patent applications WO 00/47618, WO 01/23533 and WO 00/17369 identify the beta-secretase enzyme and various methods of its use. To better understand the mechanism of action of β -secretase and help explore novel strategies for drug discovery for Alzheimer's disease, it has become important to elucidate the 3-dimensional structure of its zymogen. From the 3-dimensional structure, it has been possible to explore possible mutations in BACE which will inhibit enzyme activity as well as explore potential active site for target molecules.

SUMMARY OF THE INVENTION

[0011] The present invention relates to an isolated polypeptide sequence comprising human BACE having the modification Pro33Lys. The polypeptide can comprise at least a portion of the transmembrane domain, at least a portion of the C-terminal tail, and/or at least a portion of the signal peptide.

[0012] The invention also relates to a composition comprising an active human BACE enzyme comprising the pro-enzyme sequence of BACE having the modification Pro33Lys.

The polypeptide can comprise at least a portion of the transmembrane domain, at least a portion of the c-terminal tail, and/or at least a portion of the signal peptide.

[0013] Further, the invention relates to an isolated polypeptide of SEQ ID NO: 2.

[0014] The invention relates to an isolated polynucleotide comprising a polynucleotide sequence which, by virtue of the degeneracy of the genetic code, encodes P33K-BACE. The P33K-BACE can have the sequence of SEQ ID NO: 2. The isolated polynucleotide can comprise the nucleotide sequence of nucleotides 70 – 1365 of SEQ ID NO: 8.

[0015] The invention also relates to an expression vector comprising the polynucleotide sequence encoding P33K-BACE. The expression vector produces a P33K-BACE polypeptide when said expression vector is present in a compatible host cell. The expression vector can comprise the polypeptide sequence of SEQ ID NO: 2.

[0016] A recombinant host cell comprising the expression vector having the polynucleotide sequence encoding P33K-BACE.

[0017] A method for producing a P33K-BACE polypeptide comprising culturing the recombinant host cell having an expression vector encoding P33K-BACE under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture. The host cell can be *E. Coli*.

[0018] A method of producing active P33K-BACE comprising recovering the P33K-BACE from the culture of host cells according and diluting the polypeptide 20-50 fold with water having a temperature of about 1 to 15° C.

BRIEF DESCRIPTION OF THE FIGURES

[0019] FIG. 1 shows the amino acid sequence of human BACE [SEQ ID NO: 1]

[0020] FIG. 2 shows the amino acid sequence of an embodiment of the P33K-BACE polypeptide [SEQ ID NO: 2].

[0021] FIG. 3 shows a sequence alignment of β -secretase zymogen (pbsz) [SEQ ID NO: 3], β -secretase (1fkn) [SEQ ID NO: 4], progastricsin (1htr) [SEQ ID NO: 5] and pepsinogen (3psg) [SEQ ID NO: 6]. The lines indicate the residue pair involved in forming disulfide bond as observed in 1fkn. The codes representing the conserved residues at the active site for the aspartyl protease family are residues 93-95 and residues 289-291 for pbsz, residues 91-93 and residues 274-276 for 3psg, and residues 91-93 and residues 276-278 for 1htr. The signal peptide segments (residues 1-21 for pbsz, residues 1-16 for 1htr, and residues 1-15 for 3psg) were not included for the alignment operation because they will be cleaved off by signal peptidase during the secretory process.

[0022] FIGS. 4A and 4B are the DNA and predicted amino acid sequence of the modified recombinant BACE expressed from a pET11a-P33K-BACE construct: amino acid sequence [SEQ ID NO: 7]; DNA sequence [SEQ ID NO: 8].

DETAILED DESCRIPTION

[0023] The invention provides for a human BACE polypeptide having a mutation at amino acid position 33 (position 54 if the leader sequence is counted). "BACE" (beta-site APP-cleaving enzyme), refers to an enzyme that mediates cleavage at the beta-site of APP. This enzyme is also known as beta-secretase, Asp2, and Memapsin 2. BACE has been described, for example, in WO 00/17369, WO 00/47618 and WO 01/23533, each of which is incorporated

herein by reference in their entirety. BACE comprises an aspartyl protease and contains the classical consensus aspartyl protease active site motif (DTG/DSG).

[0024] Features of the human BACE polypeptide shown in FIG. 1 include a 21 amino acid leader (signal or pre-) sequence shown in italics, and a 24 amino acid pro-sequence, shown in bold type. T¹ marks the start of the pro-sequence. A 27 amino acid transmembrane domain is underlined, and is followed by the cytosolic C-terminal tail. Disulphide bridges are formed by cysteines (Cys¹⁹⁵-Cys³⁹⁹, Cys²⁵⁷-Cys⁴²²; and Cys³⁰⁹-Cys³⁵⁹). For the purposes of this invention BACE may optionally include (1) the complete, or a portion of, the signal sequence at the N-terminus, (2) the complete, or a portion of, the transmembrane domain, and/or (3) the complete transmembrane domain with the complete, or a portion of, the C-terminal tail. "A portion of" refers to any number of amino acids in the various sequences.

[0025] "Pro33Lys-BACE," or "P33K-BACE", refers to the enzyme including the polypeptide sequence of recombinant human BACE having a proline to lysine mutation at position 33 as shown in FIG. 2. Accordingly, when appropriately refolded, recombinant P33K-BACE is an active BACE enzyme including a peptide sequence of at least amino acids 1-432 of BACE with the P33K mutation. Pro33Lys-BACE and P33K-BACE refer to the polypeptide as it may optionally include (1) the complete, or a portion of, the signal sequence at the N-terminus, (2) the complete, or a portion of, the transmembrane domain, and/or (3) the complete transmembrane domain with the complete, or a portion of, the C-terminal tail. "A portion of" refers to any number of amino acids in the various sequences.

[0026] The "beta secretase zymogen" or the "BACE zymogen" refers to the BACE which includes the 24 amino acid pro-sequence. Generally, an enzyme will be inactivated by the existence of its pro-peptide. However, unlike most other zymogens, the existence of the pro-peptide does not seem to have a significant impact on the activity of BACE. To understand the

effect of the pro-sequence in BACE, the three dimensional structure of BACE was elucidated. From the three dimensional structure, it has been possible to explore possible mutations in BACE which will inhibit enzyme activity.

[0027] As a first step in the elucidation of the three-dimensional structure of the β -secretase zymogen, a sequence alignment was performed for the β -secretase zymogen as disclosed by Vassar et al., 1999, *Science* 286:735-741 (abbreviated as pbsz) [SEQ ID NO: 3], β -secretase (1fkn) [SEQ ID NO: 4], progastricsin (1htr) [SEQ ID NO: 5], and pepsinogen (3psg) [SEQ ID NO: 6] was performed using the PILEUP program in the GCG package (Genetic Computer Group, Madison, Wisconsin). Pepsinogen and progastricsin are pro-enzymes in the family of aspartyl proteases that includes β -secretase. The aligned result is given in FIG. 3, where the pro-peptides are underlined. For the case of pbsz, the signal peptide includes residues 1-21 (not shown), the pro-peptide includes residues 22- 45 (Bennett, et al, 2000, *Journal of Biological Chemistry* 275:37712-37717), and the main-chain includes residues 46-446 (with the active site aspartates at 93 and 289). The transmembrane and intracellular domains that follow residue 446 are outside the scope of the study.

[0028] The numbering of amino acids in sequence pbsz of FIG. 3, and the numbering of the corresponding amino acids in FIGS. 1 and 2 differ since the numbering of FIG. 3 assumes the 21 amino acid signal sequence that is shown in italics in FIG. 1. Accordingly, position 54 of pbsz in FIG. 3 is same as position 33 in FIGS. 1 and 2. Thus, while P33K-refers to the proline to lysine mutation at position 33 of BACE as shown in FIG. 1, it should be understood that, if referring to pbsz of FIG. 3, the same mutation could be referred to as P54K.

[0029] Using the alignment shown in FIG. 3, the 3-D model of the β -secretase zymogen (pbsz) was constructed from (i) the X-ray coordinates of the protease domain of β -secretase (1fkn.pdb) recently determined by Hong et al., 2000, *Science* 290:150-153, and (ii) the X-ray

coordinates of pepsinogen (3psg.pdb) determined by Hartsuck et al, 1992, *PROTEINS*:

Structure, Function and Genetics 13:1-25. The pro-segment of the pepsinogen structure provided the basis for a homology model of the β -secretase pro-segment, which was grafted onto the β -secretase protease domain, using the procedure described below.

[0030] Since the pro-peptide segment and the protease domain of the model were derived from two different templates, an operation for a smooth connection at a proper site for the two structures was needed. This was performed as follows. The template structure 3psg.pdb was superimposed onto the template structure 1fkn.pdb, using the commercial software package, MOE (Chemical Computing Ltd.). During the superimposition process the entire structure of 3psg underwent a translational and rotational motion, and hence the coordinates of 3psg changed, although the coordinates of 1fkn remained unchanged. It was observed from the superimposed pair that, starting from Gly-74 and proceeding in the C-terminal direction (the residue number is counted based on the sequence of pbsz as shown in FIG. 2), the backbone chain of 1fkn followed almost the same trajectory as that of the backbone chain of 3psg, for most of the N-terminal lobe of the bilobal structures. Moving in the N-terminal direction from Gly-74 of β -secretase, however, the structures diverged markedly. Accordingly, residue 74 of the β -secretase structure became the joining point for grafting on the pro-segment of pepsinogen (in the form of the actual β -secretase pro-segment sequence). A smooth connection between residues 16-72 of 3psg and residues 74-446 of 1fkn (FIG. 2) was realized without causing any structural conflicts. The structure thus obtained was then used as a combined template to develop the final 3-D model of the β -secretase zymogen (pbsz) by the segment matching modeling method. Levitt, M., 1992, *J. Mol. Biol.* 226:507-533.

[0031] The segment matching approach (in the MOE software) employs a database of known protein structures to build an unknown target structure based on an amino acid sequence

alignment. In this case the target structure was the β -secretase zymogen, i.e. the pro-segment plus the protease domain of β -secretase. The target structure was first broken into a set of short segments. The database was then searched for matching segments on the basis of amino acid sequence similarity and compatibility with the target structure. The process was repeated 10 times and an average model was generated, followed by energy minimization of the entire pro-enzyme to create the final model. The structure thus obtained uniquely defined the atomic coordinates of not only residues 22-45, the pro-segment of pbsz, but also the segment of residues 46-55 in the main chain that was missing in the crystal structure of 1fkn.pdb (Hong et al., 2000). Furthermore, although the majority of the protease domain (residues 75-446) of pbsz was almost identical to the corresponding sequence in 1fkn, a small transition-linking part of the protease domain (residues 56-74) was affected owing to the existence of the pro-segment. This procedure was originally shown to be highly accurate for eight test proteins ranging in size from 46 to 323 residues, where the all-atom root-mean-square deviation (RMSD) of the modeled structures was between 0.93 angstrom and 1.73 angstrom (Levitt, M., 1992, *J. Mol. Biol.* 226:507-533). This method was previously used to model the structure of the protease domain of caspase-8, at a time before the X-ray coordinates were released for caspase-3 (13). In that particular study, the atomic coordinates of the catalytic domain of caspase-3 were predicted based on the X-ray structure of caspase-1, and then the caspase-3 structure thus obtained served as a template to model the protease domain of caspase-8. After the X-ray coordinates of caspase-3 protease domain were finally released and the X-ray structure of the caspase-8 protease domain was determined (Watt, et al, 1999, *Structure* 7:1135-1143), it turned out that the RMSD for all the backbone atoms of the caspase-3 protease domain between the X-ray and predicted structures was 2.7 angstrom, while the corresponding RMSD was 3.1 angstrom for caspase-8, and only 1.2 angstrom for its core structure. This indicates that the computed structures of caspase-3 and -8 were quite close to the corresponding X-ray structures.

[0032] Since the origins of the protease domain of the model came from crystallographic coordinates, it was expected that the final energy minimized model of that domain would retain most, if not all, of the experimental attributes, and that was the case. In particular, the model retained the three pairs of disulfide bonds, i.e. Cys²¹⁶-Cys⁴²⁰, Cys²⁷⁸-Cys⁴⁴³, and Cys³³⁰-Cys³⁸⁰. This implies that the existence of the pro-peptide segment would not destroy the disulfide bonds but rather likely facilitate a proper folding for forming the three pairs disulfide bonds as observed in an active protease domain, Haniu, M. et al, 2000, *Journal of Biological Chemistry* 275:21099-21106. Proceeding in the N-terminal direction from the pro-segment attachment point, the backbone traces a path from one end of the active site cleft, toward the center, then covers over the “flap” of the active site as described in Hong et al., 2000. It then continues toward the far end of the active site, makes a turn, and returns via two helices to near its origination point. Its overall structure is somewhat similar to the pepsinogen pro-segment from which it was derived, but with a key difference described below. An overlay of the β -secretase crystal structure with the pro-enzyme model shows some differences in side chain positioning induced by the presence of the pro-segment, and very minor differences in distal positioning, likely due to the energy minimization.

[0033] Inactivation of an enzyme by its pro-peptide is generally thought to be due to physical blockage of the catalytic site, preventing access to substrate. In the case of aspartyl proteases, a pro-segment could also disrupt the catalytically-required water molecule between the two aspartates. A comparison of the 3-D structures of pepsinogen, pro-gastricsin, and the β -secretase pro-enzyme model indicates that the pro-segments of all three cover up the catalytic site, and therefore should block access to substrate. The dynamics of protein motion, however, could allow periodic unfolding of the pro-segments exposing the catalytic clefts to enable substrate processing. Yet only for the β -secretase pro-enzyme is substrate processing known to occur, so there is something unique about the positioning of its pro-segment.

[0034] As mentioned above, the substrate amide bond hydrolysis by aspartyl proteases requires the participation of a water molecule (Silverman, R. B., 2000, *The Organic Chemistry of Enzyme-Catalyzed Reactions*, Chapter 2, Academic Press, San Diego). The catalytic reaction involves (i) the β -carboxyl groups of the two Asp residues (i.e., Asp-93 and Asp-289 for the case of β -secretase) at the active site being brought in to close proximity to activate a water molecule by forming hydrogen bonds with it; (ii) the nucleophilic attack of the activated water molecule on the carbonyl carbon atom of the scissile peptide bond to form the tetrahedral intermediate; (iii) the decomposition of the tetrahedral intermediate to yield the product of cleaved peptides and active enzyme. Accordingly, before a peptide bond is cleaved by an aspartyl protease, the two Asp residues at the active site must first activate a water molecule by forming four hydrogen bonds with it.

[0035] However, for the case of pepsinogen (3psg), the two active site Asp residues, i.e., Asp-91 and Asp-274 (FIG. 2), have already formed bonds to Lys-51 of the pro-peptide by two salt bridges: one is between $O^{\delta 1}$ of Asp-91 and N^{ζ} of Lys-51, and the other between $O^{\delta 2}$ of Asp-274 and N^{ζ} of Lys-51, as clearly shown in the X-ray structure determined by Hartsuck et al. As is well known, salt-bridges are stronger than hydrogen bonds. This will certainly disrupt the two active site Asp residues in activating a water molecule, and hence the activity of the pepsinogen in cleaving a peptide bond is impeded by the existence of the pro-peptide segment. A similar situation also occurs in the case of progastricsin (1htr), where the two active site Asp residues, i.e. Asp-91 and Asp-276, have also formed two salt bridges with Lys-53 of the pro-peptide: one is between $O^{\delta 1}$ of Asp-91 and N^{ζ} of Lys-53, and the other between $O^{\delta 2}$ of Asp-276 and N^{ζ} of Lys-53, as shown by the X-ray structure determined by Ivanov et al, 1990, *Biochim. Biophys. Acta*, 1040:308-310. Accordingly, one could view the salt bridges to the aspartates as a "locking" mechanism that holds the pro-segment in place and prevents the proper positioning of a catalytic water molecule.

[0036] The microenvironment is much different in the β -secretase zymogen model, where no salt bridges are observed between the pro-peptide segment and the two active site Asp residues, *i.e.*, Asp-93 and Asp-289 (FIG. 2). According to the model, it is Pro-54 that corresponds to the Lys locations in the other two pro-enzyme structures from both sequence alignment (FIG. 2) and 3-D structure. Because the numbering of the BACE (pbsz) in FIG. 2 assumes a 21 amino acid signal sequence, Pro-54 in FIG. 2 is the same residue as Pro-33 in FIG. 1. However, a proline side-chain cannot form a salt bridge. Thus, for the case of the β -secretase zymogen, the “locking” mechanism is absent and there is no pro-segment side-chain in the location of the catalytic water position.

[0037] According to this model, therefore, the existence of the pro-peptide segment should not completely reduce the activity of β -secretase. This structural observation is supported by the recent experimental observations from the following two independent groups. Shi et al., 2001, *J. Biol. Chem.* 276:10366-10373 observed that, when assayed with a polypeptide substrate, the $k(\text{cat})/K(\text{m})$ of β -secretase with the pro-segment intact is only 2.3-fold less than β -secretase. They concluded that the pro-domain of β -secretase “does not suppress activity as in a strict zymogen but does appear to facilitate proper folding of an active protease domain.” Benjannet et al., (2001 *J. Biol. Chem.* 276:10879-10887), observed that “pro-BACE can produce significant quantities of Swedish mutant $\beta\text{APP}_{\text{sw}}$ β -secretase product C99,” and hence the pro-domain has little effect on the BACE active site.

[0038] While the absence of the “locking mechanism” in the pro-BACE model provides a possible explanation for the unusual retained activity of the pro-enzyme, the design of experiments to test the hypothesis is complicated by the fact that Pro54 (FIG. 3), or Pro33 (FIG. 1), in the pro-BACE model imparts a substantially different backbone trajectory in the region of that residue, as compared to what is observed in the two comparator crystal structures (3psg and 1htr). This observation would be expected, due to the cyclic conformational constraints of a

proline residue. Mutation of the proline to a lysine in pro-BACE would, correspondingly, also be expected to change the backbone characteristics in that region.

[0039] As shown in the following experiments, the P33K-BACE has essentially the same activity of BACE. This suggests that confirmation of the hypothesis by experimental modification of the BACE pro-segment would need to involve more than just the Pro33Lys mutation, to include one or more additional residues that would enable the nearby pro-segment backbone to more closely mimic those of the comparator pro-enzymes.

[0040] Recombinant BACE, including recombinant P33K-BACE, can be produced, for example, in *E. coli* or other suitable host cells, by expressing a construct that contains at least a portion of a cDNA encoding P33K-BACE, for example, encoding at least a portion of the amino acid sequence shown in FIG. 2. The construct can also contain additional nucleotide sequences that may, for example, assist in purification or expression of the recombinant polypeptide, as desired.

[0041] The polynucleotide construct for expressing P33K-BACE may include nucleotides coding for the signal peptide, the transmembrane domain and/or the c-terminal tail or portions thereof. Such constructs may be assembled using routine methods by those skilled in the art. The complete polynucleotide sequence of BACE may be found, for example in Vassar et al, *Science* 286:7353-741 (1999) and the PCT publications that have been incorporated by reference herein. In addition, GenBank Accession No. NM 012104 describes a number of known alleles of the BACE sequence. In addition, "silent" nucleotides substitutions may be introduced into the BACE construct sequence to enable better expression of the sequence in a desired organism, or for other reasons. Accordingly, due to the degeneracy of the genetic code, the polypeptide sequence of BACE may be expressed from a vast number of polynucleotide

sequences. The present invention is directed to any polynucleotide sequence encoding P33K-BACE.

[0042] When expressed in *E. coli*, recombinant P33K-BACE accumulates intracellularly in an insoluble form, resulting in phase-bright inclusions in the cytoplasm (inclusion bodies). The protein in the inclusion bodies can be a mixture of monomeric and multimeric forms of the protein, both reduced and oxidized.

[0043] Processes designed to recover biologically active, soluble protein from the insoluble cellular material generally include the steps of: (1) cell lysis, (2) isolation of inclusion bodies, (3) solubilization of protein from inclusion bodies, (4) refolding of solubilized protein, and (5) purification of the active protein. Each of these steps will be described in relation to the invention below.

[0044] Useful constructs for the production of P33K-BACE are designed to express a selected portion of the P33K-BACE polypeptide. The polynucleotide encoding the P33K-BACE polypeptide can be operably linked to suitable transcriptional or translational regulatory sequences in an expression construct. Regulatory sequences include transcriptional promoters, operators, enhancers, mRNA ribosomal binding sites, and other sequences that control transcription or translation. Nucleotide sequences are "operably linked" when the regulatory sequence functionally relates to the polynucleotide encoding P33K-BACE. Thus, a promoter nucleotide sequence is operably linked to a polynucleotide encoding P33K-BACE if the promoter nucleotide sequence directs the transcription of the P33K-BACE sequence.

[0045] The polynucleotide is cloned into appropriate expression vectors for expression in *E. coli*. Generally, an expression vector will include a selectable marker and an origin of replication, for propagation in *E. coli*. Expression vectors generally comprise one or more

phenotypic selectable marker genes. Such genes generally encode, for example, a protein that confers antibiotic resistance or that supplies an auxotrophic requirement.

[0046] A polynucleotide can encode a P33K-BACE polypeptide having an N-terminal methionine to facilitate expression of the recombinant polypeptide in a prokaryotic host, for example, for expression in *E. coli*. The N-terminal methionine can optionally be cleaved from the expressed P33K-BACE polypeptide. The polynucleotide can also encode other N-terminal amino acids added to the P33K-BACE polypeptide that facilitate expression in *E. coli*. Such amino acids include, but are not limited to, a T7 leader sequence, a T7-caspase 8 leader sequence, and known tags for purification such as the T7-Tag MASMTGGQQMGR [SEQ ID NO: 9] that allows binding of antibodies, or a six-histidine tag (His)₆ that allows purification by binding to nickel. Other useful peptide tags include the thioredoxin tag, hemagglutinin tag, and GST tag. These and other amino acid tags can be encoded by polynucleotides added to either terminus of the polynucleotide encoding P33K-BACE.

[0047] The polynucleotide of the expression construct can encode a P33K-BACE polypeptide that is truncated by removal of all or a portion of the C-terminal cytoplasmic tail, the transmembrane domain, the membrane proximal region, or any combination of these. The expression constructs can also encode cleavage sites for selected enzymes, to improve purification of the expressed protein or to assist in expression of the enzyme, when desired.

[0048] It has been found that active recombinant BACE protein can terminate at S⁴³², lacking the transmembrane domain and cytosolic tail region. This provides BACE in a soluble form, that is, a form that is not membrane-bound. Accordingly, in the following examples, P33K-BACE was terminated at S⁴³² to compare activity with the known active recombinant BACE.

[0049] For efficient expression, one or more codon of the polynucleotide sequence encoding P33K-BACE can be modified, using such techniques as site directed mutagenesis, to eliminate GC-rich regions of strong secondary structure known to interfere with efficient cloning or expression of the recombinant protein. Codons can also be optimized for expression in *E. coli*, for example, according to published codon preferences. Underlined nucleotides in FIG. 4A show preferred codon changes.

[0050] An expression construct containing a polynucleotide encoding P33K-BACE can be used to transform bacteria, for example *E. coli*, in order to produce P33K-BACE protein. Production of the protein can be inducible or constitutive, depending upon the control elements provided in the vectors. For example, expression constructs are transfected into a bacterial host, such as *E. coli* BL21 codon plus (DE3) RP (Stratagene) and grown in suitable media, such as Luria broth supplemented with 100 micrograms/ml ampicillin and 34 micrograms/ml chloromphenicol. When cells have grown to a desired density, in general, when the absorbance of the culture at 550 nm is between 0.5 and 0.6, expression is induced. For example, the T7 or T5 lac promoter promotes expression of the operably linked P33JK-BACE polynucleotide upon addition of IPTG (for example, to a final concentration of about 1 mM) to the culture media. After induction, for example, about three hours, the cell pellet is collected and can be stored, generally at -70° C, for later enzyme purification.

[0051] The expressed recombinant enzyme accumulates intracellularly in an insoluble form, as inclusion bodies. To recover the enzyme from insoluble cellular material, bacterial cells are pelleted from the bacterial cell culture, lysed, and the inclusion bodies are isolated from the lysed cells. The recombinant enzyme can then be isolated from the isolated inclusion bodies.

[0052] Generally, lysing of cells to obtain the protein inclusion bodies can be accomplished using a number of known methods, including mechanical and chemical techniques. Sonication

and freeze-thaw techniques are generally not practical for the volume of cells being disrupted. However, any commercially available device that uses a pressure differential to disrupt the cells, such as a French Press or a Rannie apparatus, is acceptable, assuming the overall handling capacity is similar or greater than these instruments. Detergent solubilization is not generally a practical solution, since removal of the detergent can pose a difficult challenge and may influence subsequent refolding efforts. Detergents may solubilize contaminating proteins and nucleic acids together with some or all of the protein of interest from the inclusion bodies, and thus is not a desirable option. Once the cells have been lysed, the inclusion bodies may be washed to remove protein contaminants associated with or entrapped in the inclusion bodies. If not removed, such contaminants could interfere with or prevent refolding of the enzyme.

[0053] For example, to obtain inclusion bodies, bacterial cells can be suspended in a suitable buffer that may contain a salt such as sodium chloride, a chelating agent such as EDTA, or both. Suspended cells are then lysed using, for example, a French Press or a Rannie apparatus. The insoluble cellular material obtained is washed in buffer and can be stored and frozen at -20°C overnight.

[0054] Protein aggregates (inclusion bodies) are solubilized and then refolded to obtain active protein. Reagents that can be used to solubilize P33K-BACE include urea, guanidine HCl, guanidine thiocyanate, and the like, generally at a concentration of about 6 to 8M. Reducing agents, such as beta-mercaptoethanol (BME), glutathione (gamma-Glu-Cys-Gly; or GSH, Sigma Cat. No. G-6529); or DTT (dithiothreitol, Sigma Cat.No. D-0632), and the like can also be used. These reducing agents can be used separately or in combination to provide the isolated protein in a reduced form (random coil). These agents can reduce the presence of dimers and higher molecular weight multimers, as well as reduce improper folding, for example, as a result of cysteine residues within the protein, or reduce aggregation of the protein.

[0055] Solubilization of P33K-BACE present in inclusion bodies can be achieved via treatment with a solubilizing agent at a high pH (about pH 10-11), and in the presence of a reducing agent such as BME. For example, the insoluble cellular material can be solubilized in 8 M urea, 1 mM EDTA, 1 mM glycine, 100 mM Tris base (pH 10.1-10.6), and 100 mM BME. An aliquot of sample is then diluted, for example, 10-fold, centrifuged, and the optical density (OD) at 280 nm is measured. Sample is diluted to adjust the OD to about 5.0 and pH to approximately 10.1. The sample is then diluted in 8 M urea buffer without a reducing agent. Thereafter, the reducing agent, for example, BME, is added to make the total molarity of the reducing agent about 10 mM. Dithiothreitol (DTT), reduced glutathione (GSH) and oxidized glutathione (GSSH) are added to the solution to obtain final concentrations of 10 mM DTT, 1 mM GSH, and 0.1 mM GSSG, and the pH of the solution is adjusted to 10.3-10.5. This procedure provides P33K-BACE in reduced form.

[0056] Alternatively, insoluble cellular material can be solubilized and the enzyme provided in reduced form by washing in 10 mM Tris buffer (pH 8), 1 mM EDTA (TE). Inclusion bodies are then extracted with 8 M urea, 100 mM AMPPO (pH 10.5-10.8), 1 mM glycine, 1 mM EDTA, and 100 mM BME. AMPPO is 3-[(1,1-dimethyl-2-hydroxyethyl)amino]-2-hydroxypropanesulfonic acid (Sigma Cat. No. A1911). After centrifugation, the protein concentration of the supernatant can be adjusted by dilution with buffer to approximately 5.0 at A_{280} . The protein is then diluted with 8 M urea, 100 mM AMPPO, 1 mM glycine, 1 mM EDTA, and BME at an adjusted concentration of 10 mM. Other buffer solutions can be substituted for AMPPO, such as CAPS or Tris. CAPS is (3-[cyclohexylamino]-1-propanesulfonic acid, Sigma Cat. No. C-2632).

[0057] Once the protein has been solubilized, it can be refolded into the correct conformation to provide active enzyme. Typically, refolding of an expressed recombinant enzyme can be accomplished by removing the solubilizing agent and replacing it with an

aqueous buffer, for example, by dialysis or dilution. Generally, for proteins with disulfide bridges, oxidation of the reduced protein occurs prior to or concomitant with refolding.

[0058] According to the invention, reduced protein P33K-BACE is refolded by considerably diluting (20 to 50 fold, generally 20 to 30 fold) the enzyme in a cold, aqueous solution such as water, optionally to a final concentration of about 10 μ g to 30 μ g P33K-BACE per ml of solution. Water is preferred, generally at a temperature of about 4°C to 15°C.

[0059] Generally, refolding of recombinantly expressed P33K-BACE is accomplished by permitting the diluted enzyme solution (at about pH 10-11) to rest at about 4°C-15°C in, for example, a coldroom or refrigerator for approximately 3-5 days.

[0060] For example, as shown in the Examples below, solubilized, recombinant P33K-BACE can be diluted in water (20-25 fold), optionally to a final concentration of approximately 10 micrograms to 30 micrograms P33K-BACE per ml of water, and generally at a pH of about 10.5-10.8. This mixture is maintained at temperatures of approximately 4°C to approximately 15°C for several days (3-5) and assayed periodically for enzymatic activity. Activity assays can be performed at this resting stage, starting at about 20 to 24 hours after the initial dilution step.

[0061] The refolded enzyme can be purified using standard liquid chromatography techniques, such as, for example, cation or anion exchange chromatography (available, for example, from Amersham Pharmacia Biotech), hydrophobic interaction (available, for example, from Toso Haas), dye interaction (available, for example from Sigma), ceramic hydroxyapatite (available, for example, for Bio-Rad), affinity chromatography (for example, using an inhibitor that binds active enzyme), or size exclusion chromatography (for example, Sephacryl-S100 or S200 column purification as well as resins from BioRad, Toso Haas, Sigma, and Amersham Pharmacia Biotech). One or a combination of these purification techniques can be used according to the invention to provide purified, recombinant P33K-BACE. Anion

exchange chromatography using, for example, Q-sepharose, Mono-Q, or Resource Q column purification provides useful separation.

[0062] Activity of the refolded, purified recombinant P33K-BACE can be determined by incubating the refolded enzyme with a suitable substrate under conditions to allow cleavage of the substrate. The substrate can be labeled with a detectable marker, such as a fluorescent label, to allow detection of cleavage events.

[0063] Suitable substrates are peptides that include a P33K-BACE cleavage site. For example, the synthetic peptides (SEISY-EVEFRWKK) (SEQ ID NO: 10) and (GLTNIKTEEISEISY-EVEFRWKK) (SEQ ID NO: 11) can be cleaved by the recombinant P33K-BACE (at the site marked by "-"). Additional substrates suitable for BACE cleavage include the non-limiting examples, (SEVNL-DAEFRWKK) (SEQ ID NO:12) and (GLTNIKTEEISEVNL-DAEFRWKK)(SEQ ID NO:13), containing the APP Swedish Mutation.

[0064] The substrate can be labeled with a suitable detectable marker to permit visualization of cleavage. Assays to detect activity of recombinantly produced P33K-BACE can measure retention or liberation of the detectable marker. Suitable detectable markers include, for example, radioactive, enzymatic, chemiluminescent, or fluorescent labels. In some embodiments, the substrate can include internally quenched labels that result in increased detection after cleavage of the substrate. The substrate can be modified to include a paired fluorophore and quencher including, but not limited to, 7-amino-4-methyl coumarin and dinitrophenol, respectively, such that cleavage of the substrate by P33K-BACE results in increased fluorescence as a result of physical separation of the fluorophore and quencher. Other paired fluorophores and quenchers include bodipy-tetramethylrhodamine and QSY-5 (Molecular Probes, Inc.).

[0065] In a variant of this embodiment, biotin or another suitable tag can be placed on one end of the peptide to anchor the peptide to a substrate assay plate, and a fluorophore can be placed at the other end of the peptide. Useful fluorophores include those listed herein, as well as Europium labels such as W8044 (EG&G Wallac, Inc.). One exemplary label is Oregon green that can be coupled to a cysteine residue. Cleavage of the substrate by P33K-BACE will release the fluorophore or other tag from the plate, allowing detection of an increase in retained fluorescence.

[0066] Further examples of detectable markers include a reporter protein amino acid sequence coupled to the substrate. Exemplary reporter proteins include a fluorescing protein (for example, green fluorescing proteins, luciferase, and the like) or an enzyme that is used to cleave a substrate to produce a colorimetric cleavage product. Also contemplated are tag sequences that are commonly used as epitopes for quantitative assays. Preferably, the detectable markers do not interfere with binding of P33K-BACE to the substrate, or subsequent cleavage of the substrate. For example, detectable markers can be provided in a suitable size that does not interfere with P33K-BACE activity. In some embodiments, detectable markers can be coupled to the substrate using spacers.

Examples

Example 1: Cloning of P33K-BACE

[0067] An expression construct for producing recombinant P33K-BACE protein in *E. coli* was prepared by site-directed mutagenesis from an existing construct referred as pET11a-BACE. This construct contains nucleotides coding for the following sequence: T7 tag (MASMTGGQQMGR)-GSM-BACE (A⁻⁸-S⁴³²), where the expressed BACE fragment is truncated at both N-terminal and C-terminal regions as compared with the sequence shown on FIG. 1. The insert encodes a protein lacking the transmembrane domain and the 13 N-terminal residues of the leader sequence. A methionine codon was inserted adjacent to the first BACE codon, to facilitate removal of the BACE insert with BamHI and potential subcloning for expression of the BACE sequence without the T7 tag. However, this methionine residue is not necessary if the T7 tag is included. The BACE cDNA sequence contains preferred codons for expression in *E. coli*. These codon changes are underlined in FIG. 4A.

[0068] pET11a-BACE can be prepared by techniques well known to one skilled in the art. The insert is obtained by PCR from a full length BACE cDNA. The PCR primers are designed to amplify the BACE sequence from Ala⁻⁸ to Ser⁴³², including BamHI sites for insertion into the pET11a vector (Novagen, Madison, Wisconsin). Examples of PCR primers that can be used are:

PF1 5' – GGCA GGA TCC ATG GCG GGA GTG CTG CCT GCC CA (Forward)
[SEQ ID NO: 14]

PF2 5' – GGC AGG ATC CTA TGA CTC ATC TGT CTG TGG AAT G (Reverse)
[SEQ ID NO: 15]

[0069] The PCR product is gel-purified, digested with restriction enzymes, and ligated to the corresponding sites of vector pET11a. The vector includes the T7 lac promoter, permitting induced expression on addition of IPTG.

[0070] The codon changes (underlined on FIG. 4A) can be introduced by site directed mutagenesis, using oligonucleotide primers and PCR and the method described below for mutagenesis of P33K. These changes are not necessary for successful expression of BACE in *E. coli*, but may improve yield of the re-foldable protein by eliminating rare codons.

[0071] In this embodiment of the invention, the pET11a-BACE construct was derived from two pre-existing clones. One clone, referred to as pET11a-BACE-J, contained the desired codon changes but lacked the two C-terminal cysteines. The other clone referred as pQE80L-BACE (MRGS (H)₆ GS GSIGTD- BACE: T¹-S⁴³²) contains all the required cysteines (6), but lacks Ala⁻⁸ to Gly⁻¹ (pQE80L, Qiagen). Two overlapping cDNA fragments were generated by PCR. BACE-encoding polynucleotides 37 to 880 as shown in FIGS. 4A and 4B were amplified from pET11a-BACE-J, overlapping 20 nucleotides with the remaining BACE sequence, which was amplified from pQE80L-BACE (nucleotides 861-1368 which includes a stop codon not present at this position in BACE).

[0072] The PCR primers for BACE-encoding polynucleotides 37 to 880 amplification of pET11a-BACE-J were:

PF3 5'- GGCA GGA TCC ATG GCT GGT GTT CTG CCA GCT
[SEQ ID NO: 16]

PR4 5'- T GCC ACT GTC CAC AAT GCT C [SEQ ID NO: 17]

Primer PF3 includes preferred codon changes in addition to those shown in FIG. 4A.

[0073] The overlapping segment from pQE80L-BACE including the rest of the c-terminal amino acids was amplified in a separate PCR reaction, using the primers:

PR5 - 5' GGCAGGATCCTA TGA CTC ATC TGT CTG TGG AAT 3' (reverse) [SEQ ID NO: 18]

PF6 - 5' G AGC ATT GTG GAC AGT GGC A 3' (forward)
[SEQ ID NO: 19].

[0074] The PCR conditions were as follows: one initial cycle of denaturation at 95° C, 30 seconds, 30 cycles of 30 seconds denaturation at 95° C, 30 seconds annealing at 60° C, 2 minutes extension at 72° C, followed by one cycle of 5 minutes at 72° C. The reaction components were: 1X cloned *Pfu* polymerase buffer (Stratagene), 100µM each dNTP, 100ng each primer, 10 ng template DNA, and 2Tl (20 units) of cloned *Pfu* DNA polymerase.

[0075] The products obtained from these two PCR amplifications were joined together in a third PCR amplification using the external primers PF3 [SEQ ID NO: 16] and PR5 [SEQ ID NO: 18]. This final product was gel purified, digested with BamHI and ligated into the corresponding site of vector pET11a.

[0076] The construct for expressing P33K-BACE was obtained by introducing the P33K mutation in pET11a-BACE by PCR using primers PF8 and PF9 as follows:

PF7 – 5' CCGAGGAGAAAGGCCGGAGGG (forward) [SEQ ID NO: 20]

PR8 – 5'CCCTCCGGCCTTTTCTCCTCGG (reverse) [SEQ ID NO: 21]

The codons for the substitution of Lysine for Proline at amino acid position 33 are underlined. Lysine is also coded by AAG. Accordingly the forward and reverse codons could also be AAG and CTT, respectively.

[0077] The products obtained from these two PCR amplifications were joined together in a third PCR amplification using the external primers for the pET11a vector:

PF9 - 5' TAATACGACTCACTATAGG (forward, T7 promoter)
[SEQ ID NO. 22]

PF10 - 5' GCTAGTTATTGCTCAGCGG (reverse, T7 terminator primer)
[SEQ ID NO. 23]

This final product was gel purified, digested with BamHI and ligated into the corresponding site of vector pET11a. The complete DNA and amino acid sequence for the pET11a-P33K-BACE construct is shown in FIGS. 4A and 4B. The first fifteen amino acids (underlined) correspond to the vector's T7 tag and contain a BamHI cloning site as well as an additional methionine. Codon changes as preferred for expression in *E. coli* are shown in bold type.

Example 2. Cell Incubation and Inclusion Body Harvest

[0078] Ligated DNA was transformed into *E. coli* DH5 α for propagation and DNA isolation. The resulting DNA was fully sequenced in both strands and then transformed into *E. coli* BL21 CodonPlus (DE3) Rp for expression. Cells were grown in Luria Broth (LB), pH 7.5, with 100 μ g/ml ampicillin and 34 μ g/ml chloramphenicol, at 37° C and 200 rpm (2.5 inch throw). A loop of a glycerol stock of the construct was inoculated into the media and was incubated until the A_{550} = 0.5 –0.6. Cells were collected by centrifugation, resuspended in fresh media, and used as inoculum for a secondary culture at a 1:100 dilution. When cell density reached A_{550} = 0.5 - 0.6, cells were harvested by centrifugation at room temperature and then resuspended at the same concentration in fresh LB, again containing ampicillin and chloramphenicol.

[0079] P33K-BACE expression was induced by the addition of IPTG to a final concentration of 1mM. Expression of the recombinant protein was continued for 3 hours after induction (A_{550} = 1.8 - 2.0). Cells were collected by centrifugation and stored at -80° C.

[0080] To determine the level of expression and localization of the recombinant protein, the collected centrifuged cells (cell paste) was resuspended in TE (10mM Tris HCl pH8.0, 1mM EDTA) at 1/10 of the original culture volume and sonicated. The soluble protein fraction was

separated from cell debris and insoluble proteins by centrifugation at 10,000 x g for 15 minutes. Protein in each of the fractions was analyzed by SDS-PAGE.

[0081] To obtain inclusion bodies, cultured cells were centrifuged to pellet the cells. Cell pellets were weighed from 1.0 liters of cell culture. The wet weight of the cell pellet was 2.25g. The cell pellet was resuspended in 20 ml TE. The re-suspended cell pellet was subjected to 16,000 psi in a French press. The resulting solution was centrifuged at 6000 rpm for 30 minutes and then at 2900 rpm for 30 minutes in a Sorvall SS34 rotor. The pellet was then frozen at -20°C for storage and later resuspended in 4ml 8 M urea, 100 mM AMPPO, 1 mM glycine, 1 mM EDTA, and 100 mM BME, at pH 10.5-10.8. After centrifugation at 12,900 rpm in a Sorvall SS34 rotor for 40 minutes, the protein concentration of the supernatant was diluted 50 times with the above buffer (without BME) to read approximately 5.0-7.0 at A₂₈₀.

[0082] The P33K-BACE was refolded by diluting the resuspended protein 20-25 times with approximately 1700 ml of cold H₂O and adjusting the pH to 10.1 with a few drops of HCl. This dilution was stored for approximately 3 weeks at 4-15°C prior to purification

Example 3. Purification of Refolded P33K-BACE Enzyme.

[0083] A first purification step involved a Q-Sepharose™ FAST FLOW columns to concentrate the enzyme sample and remove nucleic acids present in abundance at this stage. The 1700 ml enzyme sample was loaded onto a 10 ml Q-Sepharose™ Fast Flow column was pre-equilibrated with 10 mM Tris (pH 8.2), 0.4 M urea and NaCl to bring the conductivity to 0.9 mMhos (to match the ionic strength of the BACE protein solution). A linear gradient of 0-1.0 M NaCl was applied in the same buffer used to equilibrate the column. Fractions of 5.5 ml were collected. Elutions of protein fractions were stored in a cold room.

$$\begin{array}{ccccccc} & & \text{OH} & & \text{O} & & \\ & & | & & || & & \\ \text{H-Ser-Glu-Val-Asn-NH}-\text{CH}-\text{CH}-\text{CH}_2-\text{C}-\text{Val-Ala-Glu-Phe-Arg-Gly-Gly-Cys-OH} \\ & | & & & & & \\ & \text{CH}_3-\text{CH} & & & & & \\ & | & & & & & \\ & \text{CH}_3 & & & & & \end{array}$$

(I-1)

Example 4 – Expression of BACE in CHO cells (control)

27

Table 1: BACE Construct Asp2-2L-TM-His₆

MAQALPWLLL	WMGAGVLPAA	GTQHGIRLPLR	SGLGGAPLG	LRLPRETDEE
PEEPGRRGSF	VEMVDNLRGK	SGQGYVEMTV	GSPPQTLNLLV	DTGSSNFA
VGAAPHPFLH	RYYQRQLSST	YRDLRKGYYVP	YTQGWEGELG	TDLVSI PH
GPNVTVRANI	AAITESDKFF	INGSNWEGILG	LAYAEIARPDD	SLEPFFDS
LVKQTHVPLN	FSLQLCGAGF	PLNQSEVLASV	GGSMIIGGIDH	SLYTGSLW
YTPIRREWYY	EVIIIVRVEIN	GQDLKMDCKEY	NYDKSIVDSGT	TNLRPLPKK
VFEAAVKSII	AASSTEKFPD	GFWLGEQLVCW	QAGTTPWNIFP	VISLYLMG
EVTNQSFRII	ILPQQYLRPV	EDVATSQDDCY	KFAISQSSTGT	VMGAVIME
GFYVVFDRAR	KRIGFAVSAC	HVHDEFRTAAV	EGPFVTLDMED	CGYNIPQT
DESHHHHHH [SEQ ID NO: 24]				

Example 5. – Activity Assay

[0087] The activity of P33K-BACE expressed in *E. coli* according to the above Examples was compared to the activity of human BACE prepared as above without the P33K mutation, and to human BACE expressed in CHO cells. The results are provided in Table 2.

[0088] To assay for BACE activity, the following activity assay conditions were utilized, unless specifically indicated otherwise: 20 μ l 1 M sodium acetate (NaOAc), pH 5.0; 125 μ l H₂O; 50 μ l BACE sample containing 5-10 pmoles protein; and 5 μ l 1 mM substrate S-1 (SEQ ID NO: 10).

[0089] The 200 μ l assay reaction was incubated for 1-2 hours at 37°C. Activity was expressed as fluorescence peak area generated by the liberation of a fluorescent (Tryptophan fluorescence) product upon cleavage of Substrate S-1 by recombinant BACE. The reaction was stopped with 100 μ l of 4% TFA in H₂O. In order to separate the cleavage products and thereby detect activity of recombinant BACE, 50 microliters of the reaction mixture was injected into a Hewlett Packard Model 1100 HPLC equipped with an Alltech Rocket™ column (7 mm i.d., x 53 mm length, C₁₈, 3 μ m) pre-equilibrated with 88% Reagent A (0.1% TFA in water), 12% Reagent B (0.1% TFA in acetonitrile). The flow rate over this column was 3 ml per minute.

Table 2
Activity Assays
(Fluorescence Peak Area)

<u>E. Coli P33K-BACE</u>	<u>E. Coli BACE</u>	<u>CHO BACE</u>
38.41	31.03	83.32
26.50	45.80	85.20
32.84	31.86	78.07

[0090] The foregoing examples are illustrative of certain embodiments of the claimed invention, and do not serve to limit the invention in scope or spirit.

We claim:

1. An isolated polypeptide comprising human BACE having the modification Pro33Lys.
2. The polypeptide of claim 1 comprising at least a portion of the transmembrane domain.
3. The polypeptide of claim 1 comprising at least a portion of the C-terminal tail.
4. The polypeptide of claim 1 comprising at least a portion of the signal peptide.
5. A composition comprising an active human BACE enzyme comprising the pro-enzyme sequence of BACE having the modification Pro33Lys.
6. The composition of claim 5, wherein the BACE comprises at least a portion of the transmembrane domain.
7. The composition of claim 5, wherein the BACE, comprises at least a portion of the C-terminal tail.
8. The composition of claim 5, wherein the BACE comprises at least a portion of the signal peptide.
9. An isolated polypeptide comprising SEQ ID NO: 2.
10. An isolated polypeptide consisting of SEQ ID NO: 2.

11. An isolated polynucleotide comprising a sequence that encodes the polypeptide of claim 1.
12. An isolated polynucleotide comprising a sequence that encodes the amino acid sequence set forth in SEQ ID NO: 2.
13. An isolated polynucleotide comprising nucleotides 70 – 1365 of SEQ ID NO: 8.
14. An isolated polynucleotide consisting of nucleotides 70 – 1365 of SEQ ID NO: 8.
15. An expression vector comprising the polynucleotide of claim 11.
16. An expression vector comprising a polynucleotide sequence encoding for a Pro33Lys-BACE polypeptide, wherein said expression vector can produce the Pro33Lys-BACE polypeptide when said expression vector is present in a compatible host cell, and when the host cell is cultured under conditions that allow for production.
17. The expression vector of claim 16 wherein the Pro33Lys-BACE polypeptide that is produced comprises the polypeptide sequence of SEQ ID NO: 2.
18. A recombinant host cell comprising the expression vector of claim 15.
19. A method for producing a Pro33Lys-BACE polypeptide comprising the steps of: a) culturing the recombinant host cell of claim 18 under conditions that allow for the production of said polypeptide; and b) recovering the polypeptide from the culture.

20. The method of claim 19 wherein the host cell is *E. coli*.
21. A method of producing active Pro33Lys-BACE comprising recovering the Pro33Lys-BACE from the cultured host cell of claim 19 and diluting the polypeptide 20-50 fold with water having a temperature of about 1° C to 15° C.

1/5

FIG. 1**Amino Acid Sequence of Human BACE**

MAQALPWLLLWMGAGVLPAG T¹QHGI RLPLR SGLGGAPLGL RLPRETDEEP
EEPGRRGSFV EMVDNLRGKS GQGYVEMTV GSPPQTLNIL VDTGSSNFAV
GAAPHPFLHR YYQRQLSSTY RDLRKG VYVP YTQGWEGEL GTDLVSIPHG
PNVTVRANIA AITESDKFFI NGSNWEGILG LAYAEIARPD DSLEPFFDSL
VKQTHVPNLF SLQLCGAGFP LNQSEVLASV GGSMIIGGID HSLYTGSLWY
TPIRREWYVE VIIVRVEING QDLKMDCKEY NYDKSIVDSG TTNLRLPKKV
FEAAVKSIA ASSTEKFPDG FWLGEQLVCW QAGTTPWNIF PVISLYLMGE
VTNQSFRTI LPQQYLRPVE DVATSQDDCY KFAISQSSTG TVMGAVIMEG
FYVVFDRARK RIGFAVSACH VHDEFRTAAV EGPFTLDME DCGYNIPQTD
ES⁴³² TLMTIAYV MAAICALFML PLCLMVCQWR CLRCLRQQHD DFADDISLLK

[SEQ ID NO: 1]

FIG. 2

		TQHGIRLPLR	SGLGGAPLGL	RLPRETDEEP	30
EEKGRRGSFV	EMVDNLRGKS	GQGYVEMTV	GSPPQTLNIL	VDTGSSNFAV	80
GAAPHPFLHR	YYQRQLSSTY	RDLRKG VYVP	YTQGWEGEL	GTDLVSI PHG	130
PNVTVRANIA	AITESDKFFI	NGSNWEGILG	LAYAEIARPD	DSLEPFFDSL	180
VKQTHVPNLF	SLQLCGAGFP	LNQSEVLASV	GGSMIIGGID	HSLYTGSLWY	230
TPIRREWYYE	VIIVRVEING	QDLKMDCKEY	NYDKSIVDSG	TTNLRLPKKV	280
FEAAVKSIIA	ASSTEKFPDG	FWLGEQLVCW	QAGTTPWNIF	PVISLYLMGE	330
VTNQSFRTI	LPQQYLRPVE	DVATSQDDCY	KFAISQSSTG	TVMGAVIMEG	380
FYVVFDRARK	RIGFAVSACH	VHDEFRTAAV	EGPFVTL DME	DCGYNIPQTD	430
ES	[SEQ ID NO: 2]				432

3/5

FIG. 3

pbsz	----- ²² TQ	HGIRLPLRSG	LGGAPLGLRL	⁴⁶ PRÉTDEEPEE	⁵⁶ FGRRGSFVEM	VDN..LRGKS
lfkn	----- ¹⁷				⁵³ -RRGSFVEM	VDN..LRGKS
lhttr	--- ¹⁷ AVVKVPL	KKFKSIRETM	KEKGLLGEFL	R.THKYDPAW	KYRFGDLS..	VTYEPMA.YM
3psg	--- ¹⁶ LVKVPL	VRKKSRLRQNL	IKDGKLDKDFL	K.THKHNPAS	⁵¹ KY.FPEAAAL	⁶⁰ IGDEPLENYL
pbsz	⁷⁶ GQGYVEMTV	GSPPQTLNIL	⁹³ VDTGSSNFAV	GAAPHPFL..	..HRYYQRQL	SSTYRDLRKG
lfkn	GQGYVEMTV	GSPPQTLNIL	VDTGSSNFAV	GAAPHPFL..	..HRYYQRQL	SSTYRDLRKG
lhttr	DAAFYGEISI	GTPPQNFLVL	FDTGSSNLWV	PSVYCQSQAC	TSHSRFPNPSE	SSTYSTNGQT
3psg	⁷² DTEYFGTIGI	GTPAQDFTVI	⁹¹ FDTGSSNLWV	PSVYCSSLAC	SDHNQFNPDD	SSTFEATSQE
pbsz	VYVPYTQGKW	EGELGTDLVS	IPHGPNVTVR	ANIAAITESD	KFFINGSNWE	GILGLAYAEI
lfkn	VYVPYTQGKW	EGELGTDLVS	IPHGPNVTVR	ANIAAITESD	KFFINGSNWE	GILGLAYAEI
lhttr	FSLQYGSGL	TGFFGYDTLT	V.QSIQVPNQ	EFGLSENEPG	TNFVYAQ.FD	GIMGLAYPAL
3psg	LSITYGTGSM	TGILGYDTVQ	V.GGISDTNQ	IFGLSETEPG	SFLYYAP.FD	GILGLAYPSI
pbsz	ARPDDSLEPF	FDSL VKQTHV	²¹⁶ PN.LFSLHLC	GAGFPLNQSE	VLASVGGSMI	IGGIDHSLYT
lfkn	ARPDDSLEPF	FDSL VKQTHV	PN.LFSLQLC	GAGFPLNQSE	VLASVGGSMI	IGGIDHSLYT
lhttr	SV..DEATTA	MQGMVQEGAL	TSPVFSVYL.SNQQG.	...SSGAVV	FGGVDSLYT
3psg	SA..SGATPV	FDNLWDQGLV	SQDLFSVYL.SSND..	...DSGSVVL	LGGIDSSYYT
pbsz	GSLWYTPIRR	EWYYEVIIVR	VEINGQDLKM	²⁷⁸ DCKEYNYDKS	²⁸⁹ IVDSGTTNLR	LPKKVFEEAV
lfkn	GSLWYTPIRR	EWYYEVIIVR	VEINGQDLKM	DCKEYNYDKS	IVDSGTTNLR	LPKKVFEEAV
lhttr	GQIYWAPVTQ	ELYWQIGIEE	FLIGGQASGW	CSEGCQ...A	IVDTGTSLLT	VPQQYMSALL
3psg	GSLNWVPVSV	EGYWQITLDS	ITMDGETIA.	CSGGCQ...A	²⁷⁴ IVDTGTSLLT	GPTSAIANIQ
pbsz	KSIIKAASSTE	KFPDGFWLGE	³³⁰ QLVCWQAGTT	PWNIFPVISL	YLMGEVTNQS	FRITILPQQY
lfkn	KSIIKAASSTE	KFPDGFWLGE	QLVCWQAGTT	PWNIFPVISL	YLMGEVTNQS	FRITILPQQY
lhttr	QATGA....Q	EDEYGQFL..	.VNCSIQNL	PSLTF.....IING	VEFPLPPSSY
3psg	SDIGA....S	ENSDGEMV..	.ISCSSIDSL	PDIVF.....TIDG	VQYPLSPSAY
pbsz	LRPVEDV...	³⁸⁰ .ATSQDDCYK	FAISQSSTGT	VMGAVIMEGF	⁴²⁰ YVVFDRARKR	IGFAVSACHV
lfkn	LRPVEDV...	.ATSQDDCYK	FAISQSSTGT	VMGAVIMEGF	YVVFDRARKR	IGFAVSACHV
lhttr	I..LSN..NG	YCTVGVEPTY	LSSQNGQPLW	ILGDVFLRSY	YSVYDLGNNR	VGFATAA---
3psg	I..LQD..DD	SCTSGFEGMD	VPTSSGE.LW	ILGDVFIRQY	YTVFDRANNK	VGLAPVA---
pbsz	HDEFRTAAVE	GPFVTLDMED	⁴⁴³ CGYN			
lfkn	HDEFRTAAVE	GPFVTLDMED	CGYN			
lhttr	-----	-----	----			
3psg	-----	-----	----			

FIG. 4A

**DNA and predicted amino acid sequence of the modified recombinant
BACE expressed from pET11a-BACE-Pro33Lys construct**

Met	Ala	Ser	Met	Thr	Gly	Gly	Gln	Gln	Met	Gly	Arg	Gly	Ser	Met	-8			Ala	Gly	Val	Leu	Pro	-4
atg	gct	agc	atg	act	ggg	gga	cag	caa	atg	ggg	cgc	gga	tcc	atg	gcg	gga	gtg	ctg	cct				60
Ala	His	Gly	Thr	Gln	His	Gly	Ile	Arg	Leu	Pro	Leu	Arg	Ser	Gly	Leu	Gly	Gly	Ala	Pro				17
gcc	cac	ggg	acc	caa	cat	ggg	att	cgt	ctg	cca	ctg	cgt	agc	ggg	ctg	ggg	ggg	gct	cca				120
Leu	Gly	Leu	Arg	Leu	Pro	Arg	Glu	Thr	Asp	Glu	Glu	Pro	Glu	Glu	Lys	Gly	Arg	Arg	Gly				37
ctg	ggg	ctg	cgt	ctg	ccc	cgg	gag	acc	gac	gaa	gag	ccc	gag	gag	aaa	ggc	cgg	agg	ggc				180
Ser	Phe	Val	Glu	Met	Val	Asp	Asn	Leu	Arg	Gly	Lys	Ser	Gly	Gln	Gly	Tyr	Tyr	Val	Glu				57
agc	ttt	gtg	gag	atg	gtg	gac	aac	ctg	agg	ggc	aag	tgc	ggg	cag	ggc	tac	tac	gtg	gag				240
Met	Thr	Val	Gly	Ser	Pro	Pro	Gln	Thr	Leu	Asn	Ile	Leu	Val	Asp	Thr	Gly	Ser	Ser	Asn				77
atg	acc	gtg	ggc	agc	ccc	ccg	cag	acg	ctc	aac	atc	ctg	gtg	gat	aca	ggc	agc	agt	aac				300
Phe	Ala	Val	Gly	Ala	Ala	Pro	His	Pro	Phe	Leu	His	Arg	Tyr	Tyr	Gln	Arg	Gln	Leu	Ser				97
ttt	gca	gtg	ggg	gct	gcc	ccc	cac	ccc	ttc	ctg	cat	cgc	tac	tac	cag	agg	cag	ctg	tcc				360
Ser	Thr	Tyr	Arg	Asp	Leu	Arg	Lys	Gly	Val	Tyr	Val	Pro	Tyr	Thr	Gln	Gly	Lys	Trp	Glu				117
agc	aca	tac	cgg	gac	ctc	cgg	aag	ggc	gtg	tat	gtg	ccc	tac	acc	cag	ggc	aag	tgg	gaa				420
Gly	Glu	Leu	Gly	Thr	Asp	Leu	Val	Ser	Ile	Pro	His	Gly	Pro	Asn	Val	Thr	Val	Arg	Ala				137
ggg	gag	ctg	ggc	acc	gac	ctg	gta	agc	atc	ccc	cat	ggc	ccc	aac	gtc	act	gtg	cgt	gcc				480
Asn	Ile	Ala	Ala	Ile	Thr	Glu	Ser	Asp	Lys	Phe	Phe	Ile	Asn	Gly	Ser	Asn	Trp	Glu	Gly				157
aac	att	gct	gcc	atc	act	gaa	tca	gac	aag	ttc	ttc	atc	aac	ggc	tcc	aac	tgg	gaa	ggc				540
Ile	Leu	Gly	Leu	Ala	Tyr	Ala	Glu	Ile	Ala	Arg	Pro	Asp	Asp	Ser	Leu	Glu	Pro	Phe	Phe				177
atc	ctg	ggg	ctg	gcc	tat	gct	gag	att	gcc	agg	cct	gac	gac	tcc	ctg	gag	cct	ttc	ttt				600
Asp	Ser	Leu	Val	Lys	Gln	Thr	His	Val	Pro	Asn	Leu	Phe	Ser	Leu	Gln	Leu	Cys	Gly	Ala				197
gac	tct	ctg	gta	aag	cag	acc	cac	ggt	ccc	aac	ctc	ttc	tcc	ctg	cag	ctt	tgt	ggg	gct				660
Gly	Phe	Pro	Leu	Asn	Gln	Ser	Glu	Val	Leu	Ala	Ser	Val	Gly	Gly	Ser	Met	Ile	Ile	Gly				217
ggc	ttc	ccc	ctc	aac	cag	tct	gaa	gtg	ctg	gcc	tct	gtc	gga	ggg	agc	atg	atc	att	gga				720
Gly	Ile	Asp	His	Ser	Leu	Tyr	Thr	Gly	Ser	Leu	Trp	Tyr	Thr	Pro	Ile	Arg	Arg	Glu	Trp				237
ggg	atc	gac	cac	tgc	ctg	tac	aca	ggc	agt	ctc	tgg	tat	aca	ccc	atc	cgg	cgg	gag	tgg				780
Tyr	Tyr	Glu	Val	Ile	Ile	Val	Arg	Val	Glu	Ile	Asn	Gly	Gln	Asp	Leu	Lys	Met	Asp	Cys				257
tat	tat	gag	gtc	atc	att	gtg	cgg	gtg	gag	atc	aat	gga	cag	gat	ctg	aaa	atg	gac	tgc				840
Lys	Glu	Tyr	Asn	Tyr	Asp	Lys	Ser	Ile	Val	Asp	Ser	Gly	Thr	Thr	Asn	Leu	Arg	Leu	Pro				277
aag	gag	tac	aac	tat	gac	aag	agc	att	gtg	gac	agt	ggc	acc	acc	aac	ctt	cgt	ttg	ccc				900
Lys	Lys	Val	Phe	Glu	Ala	Ala	Val	Lys	Ser	Ile	Lys	Ala	Ala	Ser	Ser	Thr	Glu	Lys	Phe				297
aag	aaa	gtg	ttt	gaa	gct	gca	gtc	aaa	tcc	atc	aag	gca	gcc	tcc	tcc	acg	gag	aag	ttc				960

5/5

FIG. 4B

```

Pro Asp Gly Phe Trp Leu Gly Glu Gln Leu Val Cys Trp Gln Ala Gly Thr Thr Pro Trp   317
cct gat ggt ttc tgg cta gga gag cag ctg gtg tgc tgg caa gca ggc acc acc cct tgg 1020

Asn Ile Phe Pro Val Ile Ser Leu Tyr Leu Met Gly Glu Val Thr Asn Gln Ser Phe Arg   337
aac att ttc cca gtc atc tca ctc tac cta atg ggt gag gtt acc aac cag tcc ttc cgc 1080

Ile Thr Ile Leu Pro Gln Gln Tyr Leu Arg Pro Val Glu Asp Val Ala Thr Ser Gln Asp   357
atc acc atc ctt ccg cag caa tac ctg cgg cca gtg gaa gat gtg gcc acg tcc caa gac 1140

Asp Cys Tyr Lys Phe Ala Ile Ser Gln Ser Ser Thr Gly Thr Val Met Gly Ala Val Ile   377
gac tgt tac aag ttt gcc atc tca cag tca tcc acg ggc act gtt atg gga gct gtt atc 1200

Met Glu Gly Phe Tyr Val Val Phe Asp Arg Ala Arg Lys Arg Ile Gly Phe Ala Val Ser   397
atg gag ggc ttc tac gtt gtc ttt gat cgg gcc cga aaa cga att ggc ttt gct gtc agc 1260

Ala Cys His Val His Asp Glu Phe Arg Thr Ala Ala Val Glu Gly Pro Phe Val Thr Leu   417
gct tgc cat gtg cac gat gag ttc agg acg gca gcg gtg gaa ggc cct ttt gtc acc ttg 1320

Asp Met Glu Asp Cys Gly Tyr Asn Ile Pro Gln Thr Asp Glu Ser End   432 [SEQ ID NO:7]
gac atg gaa gac tgt ggc tac aac att cca cag aca gat gag tca   1365 [SEQ ID NO:8]

```

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.